From the Research
Safety of Semaglutide (Wegovy) during Ramadan Fasting
There are no direct studies on the safety of semaglutide (Wegovy) during Ramadan fasting. However, some studies have investigated the safety and efficacy of similar medications, such as GLP-1 agonists, during Ramadan fasting.
- GLP-1 agonists, which are similar to semaglutide, have been found to be safe and effective during Ramadan fasting, with a reduced risk of hypoglycemia 1, 2.
- A study on the safety and effectiveness of newer antidiabetic medications during Ramadan fasting found that GLP-1 agonists, such as liraglutide and exenatide, were associated with a reduced risk of hypoglycemia 2.
- Another study found that GLP-1 agonists, DPP-4 inhibitors, and SGLT-2 inhibitors were safe and effective during Ramadan fasting, with a reduced risk of hypoglycemia and improved glycemic control 1.
- However, it is essential to note that semaglutide is a specific medication, and its safety during Ramadan fasting should be evaluated on an individual basis, taking into account the patient's medical history, medication regimen, and other factors.
General Considerations for Diabetes Management during Ramadan
- Patients with diabetes who fast during Ramadan should be closely monitored for hypoglycemia, hyperglycemia, and dehydration 1, 3, 4.
- Medication adjustments and dietary counseling may be necessary to prevent complications and ensure safe fasting 3, 2.
- Patients should be educated on glucose monitoring, medication management, and dehydration prevention to minimize the risks associated with fasting during Ramadan 3, 4.